ISACA
Privacy is a critical component of digital trust – it contributes to a more positive reputation and fewer cybersecurity incidents for the companies that prioritise it. Global digital trust association, ISACA, believes that businesses are aware of its significance; according to its 2023 “Privacy in Practice” report published today, 87% of organisations in Europe offer privacy awareness training to employees. But they’re missing the mark as most (94%) companies recognise a privacy skills gap within their business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005916/en/
ISACA surveyed more than 1,800 professionals worldwide—including 375 in Europe—who work in data privacy or have detailed knowledge of the data privacy function within their organisations to demonstrate current perspectives on privacy staffing, organisation structure, frameworks and policies, budgets, training, and data breaches. Learn more about the key findings and the business benefits of privacy by design at www.isaca.org/privacy-month-2023. (Graphic: ISACA)
ISACA’s “Privacy in Practice” report explores the state of enterprise privacy by examining trends around privacy teams, privacy-related challenges, privacy by design and the future of privacy.
The report reveals that as it stands, more than half (59%) of technical privacy teams in Europe are understaffed. Building these departments is a challenge, with 1 in 5 businesses saying it takes them more than six months to fill a technical privacy position and 41% saying their privacy budgets are underfunded.
The most reported privacy failures include a lack of training or poor training (49%); data breaches (38%); and not practicing privacy by design (39%). With just 38% of business leaders confident in their organisation’s ability to ensure the privacy of its sensitive data, businesses need to change their approach to closing the privacy skills gap or risk jeopardising their relationships with customers and damaging the reputation of the business.
Chris Dimitriadis, Global Chief Strategy Officer, ISACA says: “Privacy professionals play a key role in establishing digital trust. As technology advances, introducing new complexities and threats and as the cyberthreat landscape increases in size and sophistication, demand for these individuals is only going to grow. Heightened privacy skills demand is good news for candidates with privacy technology knowledge but also bad news for businesses that are struggling to close the privacy skills gap. As our new research highlights, businesses need to consider changing their training programmes and adopt privacy by design to limit the number of privacy breaches, build digital trust, and set the business up for long term success.”
Tony Hughes, ISACA Emerging Trends Working Group Member, adds: “Only searching for candidates with specific experience and technical privacy skills is an outdated mindset – it immediately limits businesses to a small pool of people. Instead, organisations need to lean on reskilling people in non-privacy roles, using contract employees and focusing on individuals with the right soft skills to reduce the privacy skills gap.”
Notes to Editors
All figures are based on fieldwork conducted by ISACA. Fieldwork was undertaken in Q4 2022, amongst 1890 global privacy professionals, including 375 in Europe.
ISACA’s Privacy in Practice report is now available to download here.
About ISACA
For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organisations, and build a more trusted and ethical digital world. ISACA leverages the expertise of its more than 165,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality, with a presence in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for under resourced and underrepresented populations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005916/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
